Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (151-160 of 280) with videos related to

Pageof 28
Sort By:
Blood Advances|September 17, 2021
Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLIChristian R Schultze-Florey, Leonie Kuhlmann, Solaiman Raha, et al.
Leukemia|November 3, 2021
Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.
The Lancet. Oncology|October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines CommitteeJaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Scientific Reports|October 7, 2025
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flagsJanna M Siemer, Lea Grote-Levi, Anja Hänselmann, et al.
Leukemia|June 25, 2020
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemiaFrederik Damm, Michael Heuser, Michael Morgan, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Haematologica|February 4, 2017
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerizationJulia Schanda, Chun-Wei Lee, Katharina Wohlan, et al.
Frontiers in Immunology|April 10, 2023
Non-viral <i>TRAC</i>-knocked-in CD19<sup>KI</sup>CAR-T and gp350<sup>KI</sup>CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: <i>In vivo</i> cellular dynamics and potencyTobias Braun, Alina Pruene, Milita Darguzyte, et al.
Pageof 28

Showing results (151-160 of 280) with videos related to

Sort By:
Pageof 28
Blood Advances|September 17, 2021
Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLIChristian R Schultze-Florey, Leonie Kuhlmann, Solaiman Raha, et al.
Leukemia|November 3, 2021
Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.
The Lancet. Oncology|October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines CommitteeJaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Scientific Reports|October 7, 2025
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flagsJanna M Siemer, Lea Grote-Levi, Anja Hänselmann, et al.
Leukemia|June 25, 2020
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemiaFrederik Damm, Michael Heuser, Michael Morgan, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Haematologica|February 4, 2017
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerizationJulia Schanda, Chun-Wei Lee, Katharina Wohlan, et al.
Frontiers in Immunology|April 10, 2023
Non-viral <i>TRAC</i>-knocked-in CD19<sup>KI</sup>CAR-T and gp350<sup>KI</sup>CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: <i>In vivo</i> cellular dynamics and potencyTobias Braun, Alina Pruene, Milita Darguzyte, et al.
Pageof 28